[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616082":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":63,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":26,"studyType":83,"phases":84,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":95,"whyStopped":26,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Duke University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Glucagon infusion during hyperinsulinemic clamp","EXPERIMENTAL","Glucagon infusion either graded (0.2→0.4→0.6 ng\u002Fkg\u002Fmin) or continuous (0.4 ng\u002Fkg\u002Fmin) during the final 90 minutes of a hyperinsulinemic glucose clamp. The graded or continuous glucagon infusions are given as a component of 2 separate protocols.",[13],"Drug: Glucagon",{"label":15,"type":16,"description":17,"interventionNames":18},"Saline infusion during hyperinsulinemic clamp","PLACEBO_COMPARATOR","Saline infusion during the final 90 minutes of an otherwise identical clamp procedure.",[19],"Drug: Saline (placebo)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Glucagon","Glucagon infusion either graded (0.2→0.4→0.6 ng\u002Fkg\u002Fmin) or continuous (0.4 ng\u002Fkg\u002Fmin) during the final 90 minutes of a hyperinsulinemic glucose clamp. The graded or continuous glucagon infusions are given as a component of 2 separate protocols. Glucagon prepared per pharmacy\u002Fbedside protocol.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Saline (placebo)","IV saline infusion during clamp for 90 minutes as control.",[15],[32],{"name":33,"affiliation":5,"role":34},"David D'Alessio, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Johanna Johnson, MS","CONTACT","919-660-6766","johanna.johnson@duke.edu",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Alyssa Sudnick, MS","919-660-6769","alyssa.sudnick@duke.edu",[46],{"facility":47,"status":26,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Duke Center for Living","Durham","North Carolina","27705","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-78.89862,35.99403,{"lat":57,"lon":56},[60,61,62],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":64,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[66],{"name":67,"class":68},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100616082","phase-1-studies-of-insulin-and-glucagon-action-in-the-liver-100616082",false,"NCT07300982","Studies of Insulin and Glucagon Action in the Liver","SIGNAL","Inclusion Criteria:\n\n* Healthy adults age 18-45 years\n* Body Mass Index (BMI) \\\u003C 27.0 kg\u002Fm²\n* Fasting plasma glucose ≤ 95 mg\u002FdL or HbA1c ≤ 5.8% as measured at screening visit\n\nExclusion Criteria:\n\n* Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders\n* No personal history of diabetes or pancreatitis\n* No personal history of cardiac, gastrointestinal, renal or liver disease\n* No history of diabetes among any first-degree family members\n* Renal insufficiency (eGFR \\\u003C 60 mL\u002Fkg\u002Fmin)\n* Anemia (hematocrit \\\u003C 34%) as measured at screening visit\n* Pregnant females\n* Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)",true,"ALL","18 Years","45 Years",{"count":81,"type":82},40,"ESTIMATED","INTERVENTIONAL",[85,86],"PHASE1","PHASE2","This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose.\n\nParticipants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.",[89],"Diabetes (DM)",[91,92,23,93,94],"Glucose metabolism","Hepatic insulin sensitivity","Insulin","hepatic glucose production","NOT_YET_RECRUITING","2026-08-03",{"date":98,"type":99},"2026-08-05","ACTUAL",{"date":101,"type":82},"2026-10",{"date":103,"type":82},"2029-12",{"name":5,"class":6},1]